Journal article
SELIMETRY—a multicentre I-131 dosimetry trial: a clinical perspective
Abstract
Treatment options for patients with thyroid cancer that is no longer sensitive to iodine therapy are limited. Those treatments which currently exist are associated with significant toxicity. The SELIMETRY trial (EudraCT No 2015-002269-47) aims to investigate the role of the MEK inhibitor Selumetinib in resensitizing advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. Patients deemed to have sufficient iodine uptake …
Authors
Wadsley J; Gregory R; Flux G; Newbold K; Du Y; Moss L; Hall A; Flanagan L; Brown SR
Journal
British Journal of Radiology, Vol. 90, No. 1073,
Publisher
Oxford University Press (OUP)
Publication Date
May 2017
DOI
10.1259/bjr.20160637
ISSN
0007-1285